Company intelligence / Profile preview

Diurnal Group plc

Ownership: Public · DNL
Development stage: Commercial

Overview

Diurnal has successfully developed and commercialized Alkindi, a child-optimized preparation of hydrocortisone, which has been approved in Europe and the US. The company has also developed Chronocort for adult CAH patients, which mimics the circadian release profile of cortisol and was awaiting EMA approval as of 2020.

Therapeutic areas: Endocrinology
Modalities: Small molecule drug
Industry: Biotech

Drug pipeline

3 assets

hydrocortisone

Commercial

Indications: Pediatric adrenal insufficiency

2 more assets in the full pipeline.

Request access →

Partnerships

Eton Pharmaceuticals (US partner for Alkindi)

Financials

Market cap: $489.9M
Enterprise value: $489.9M

Beyond the preview

Go deeper on Diurnal Group plc.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Diurnal Group plc.

Explore the full profile